发明名称 Cyclin dependent kinase inhibitors
摘要 A range is disclosed of pyrimidine derivatives (I) which can act as inhibitors of cyclin dependent kinases (CDK's) and which thereby can provide useful therapeutic compounds for use in treatment of tumours or other cell proliferation disorders. The compounds of this invention bind to CDK molecules in a manner that appears to differ from that of known CDK inhibitors such as olomoucine and roscovitine. In formula (I), X is O, S or CHRx where Rx is H or C1-4 alkyl; D is H or NZ1Z2 where Z1 and Z2 are each independently H, C1-4 alkyl, C1-4 hydroxyalkyl, optionally substituted aryl or optionally substituted aralkyl; A is selected from H, C1-4 alkyl, C1-4 alkoxy, hydroxy, CH2(CH2)nOH (n=1-4), and NRa1Ra2 where Ra1 and Ra2 are each independently H or C1-4 alkyl; Y is or includes an optionally substituted 4- to 8-membered carbocyclic or heterocyclic ring; D' is H or NZ3Z4 where Z3 and Z4 are each independently H, C1-4 alkyl, C1-4 hydroxyalkyl, optionally substituted aryl or optionally-substituted aralkyl; E is selected from NO, NO2, N=N-Ar where Ar is an optionally substituted aryl or optionally substituted aralkyl, NRe1Re2 or Nre1Nre2Re3 (Re1, Re2 and Re3 each being independently H, C1-4 alkyl, C1-4 hydroxyalkyl, an optionally substituted aryl or an optionally substituted aralkyl), C(Re)=U (Re being hydrogen, C1-4 alkyl or substituted alkyl, e.g. hydroxyalkyl, or an unsubstituted or substituted aryl or aralkyl, e.g. benzyl, and U being selected from O, Nre', NORe' and N-NRe'Re'' where Re' and Re'' are each independently H, C1-4 alkyl or CONH2), T, CH2T, CHT2 and CT3, where T is a halide I, Br, Cl or F.
申请公布号 US6677345(B1) 申请公布日期 2004.01.13
申请号 US20000671676 申请日期 2000.09.28
申请人 CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED 发明人 GRIFFIN ROGER J;CALVERT ALAN H;CURTIN NICOLA J;NEWELL DAVID R;GOLDING BERNARD T;ENDICOTT JANE A;NOBLE MARTIN E M;BOYLE FRANCIS T;JEWSBURY PHILIP J
分类号 A61K31/505;A61P35/00;C07D239/02;C07D239/48;C07D239/50;C07H19/167;(IPC1-7):A61K31/505;C07D487/00 主分类号 A61K31/505
代理机构 代理人
主权项
地址